209 related articles for article (PubMed ID: 33858992)
1. Structure reveals the activation mechanism of the MC4 receptor to initiate satiation signaling.
Israeli H; Degtjarik O; Fierro F; Chunilal V; Gill AK; Roth NJ; Botta J; Prabahar V; Peleg Y; Chan LF; Ben-Zvi D; McCormick PJ; Niv MY; Shalev-Benami M
Science; 2021 May; 372(6544):808-814. PubMed ID: 33858992
[TBL] [Abstract][Full Text] [Related]
2. Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach.
Falls BA; Zhang Y
ACS Chem Neurosci; 2019 Mar; 10(3):1055-1065. PubMed ID: 30048591
[TBL] [Abstract][Full Text] [Related]
3. Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor.
Hammad MM; Mohammad A; Alam-Eldin N; Madhu D; Al-Mulla F; Abu-Farha M; Abubaker J
Life Sci; 2022 Oct; 307():120857. PubMed ID: 35931197
[TBL] [Abstract][Full Text] [Related]
4. Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity.
Nargund RP; Strack AM; Fong TM
J Med Chem; 2006 Jul; 49(14):4035-43. PubMed ID: 16821763
[No Abstract] [Full Text] [Related]
5. Structures of active melanocortin-4 receptor-Gs-protein complexes with NDP-α-MSH and setmelanotide.
Heyder NA; Kleinau G; Speck D; Schmidt A; Paisdzior S; Szczepek M; Bauer B; Koch A; Gallandi M; Kwiatkowski D; Bürger J; Mielke T; Beck-Sickinger AG; Hildebrand PW; Spahn CMT; Hilger D; Schacherl M; Biebermann H; Hilal T; Kühnen P; Kobilka BK; Scheerer P
Cell Res; 2021 Nov; 31(11):1176-1189. PubMed ID: 34561620
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
Collet TH; Dubern B; Mokrosinski J; Connors H; Keogh JM; Mendes de Oliveira E; Henning E; Poitou-Bernert C; Oppert JM; Tounian P; Marchelli F; Alili R; Le Beyec J; Pépin D; Lacorte JM; Gottesdiener A; Bounds R; Sharma S; Folster C; Henderson B; O'Rahilly S; Stoner E; Gottesdiener K; Panaro BL; Cone RD; Clément K; Farooqi IS; Van der Ploeg LHT
Mol Metab; 2017 Oct; 6(10):1321-1329. PubMed ID: 29031731
[TBL] [Abstract][Full Text] [Related]
7. Structural Complexity and Plasticity of Signaling Regulation at the Melanocortin-4 Receptor.
Kleinau G; Heyder NA; Tao YX; Scheerer P
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32785054
[TBL] [Abstract][Full Text] [Related]
8. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.
Ayers KL; Glicksberg BS; Garfield AS; Longerich S; White JA; Yang P; Du L; Chittenden TW; Gulcher JR; Roy S; Fiedorek F; Gottesdiener K; Cohen S; North KE; Schadt EE; Li SD; Chen R; Van der Ploeg LHT
J Clin Endocrinol Metab; 2018 Jul; 103(7):2601-2612. PubMed ID: 29726959
[TBL] [Abstract][Full Text] [Related]
9. Setmelanotide: First Approval.
Markham A
Drugs; 2021 Feb; 81(3):397-403. PubMed ID: 33638809
[TBL] [Abstract][Full Text] [Related]
10. Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R).
Hainer V; Aldhoon Hainerová I; Kunešová M; Taxová Braunerová R; Zamrazilová H; Bendlová B
Physiol Res; 2020 Sep; 69(Suppl 2):S245-S254. PubMed ID: 33094623
[TBL] [Abstract][Full Text] [Related]
11. Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment.
Kühnen P; Krude H; Biebermann H
Trends Mol Med; 2019 Feb; 25(2):136-148. PubMed ID: 30642682
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity.
René P; Le Gouill C; Pogozheva ID; Lee G; Mosberg HI; Farooqi IS; Valenzano KJ; Bouvier M
J Pharmacol Exp Ther; 2010 Dec; 335(3):520-32. PubMed ID: 20826565
[TBL] [Abstract][Full Text] [Related]
13. A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation.
Reininghaus N; Paisdzior S; Höpfner F; Jyrch S; Cetindag C; Scheerer P; Kühnen P; Biebermann H
Biomolecules; 2022 Aug; 12(8):. PubMed ID: 36009013
[TBL] [Abstract][Full Text] [Related]
14. The melanocortin pathway and energy homeostasis: From discovery to obesity therapy.
Yeo GSH; Chao DHM; Siegert AM; Koerperich ZM; Ericson MD; Simonds SE; Larson CM; Luquet S; Clarke I; Sharma S; Clément K; Cowley MA; Haskell-Luevano C; Van Der Ploeg L; Adan RAH
Mol Metab; 2021 Jun; 48():101206. PubMed ID: 33684608
[TBL] [Abstract][Full Text] [Related]
15. Exposure of MC4R to agonist in the endoplasmic reticulum stabilizes an active conformation of the receptor that does not desensitize.
Granell S; Molden BM; Baldini G
Proc Natl Acad Sci U S A; 2013 Dec; 110(49):E4733-42. PubMed ID: 24248383
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological chaperone action in humanized mouse models of MC4R-linked obesity.
René P; Lanfray D; Richard D; Bouvier M
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434184
[TBL] [Abstract][Full Text] [Related]
17. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans.
Srinivasan S; Lubrano-Berthelier C; Govaerts C; Picard F; Santiago P; Conklin BR; Vaisse C
J Clin Invest; 2004 Oct; 114(8):1158-64. PubMed ID: 15489963
[TBL] [Abstract][Full Text] [Related]
18. The MC4 receptor and control of appetite.
Adan RA; Tiesjema B; Hillebrand JJ; la Fleur SE; Kas MJ; de Krom M
Br J Pharmacol; 2006 Dec; 149(7):815-27. PubMed ID: 17043670
[TBL] [Abstract][Full Text] [Related]
19. Melanocortin receptor 4 deficiency affects body weight regulation, grooming behavior, and substrate preference in the rat.
Mul JD; van Boxtel R; Bergen DJ; Brans MA; Brakkee JH; Toonen PW; Garner KM; Adan RA; Cuppen E
Obesity (Silver Spring); 2012 Mar; 20(3):612-21. PubMed ID: 21527895
[TBL] [Abstract][Full Text] [Related]
20. The melanocortin pathway and control of appetite-progress and therapeutic implications.
Baldini G; Phelan KD
J Endocrinol; 2019 Apr; 241(1):R1-R33. PubMed ID: 30812013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
